Clinical Handbook of Psychotropic Drugs for Children and Adolescents

New edition released May 2023

Quick and comprehensive information on psychotropic drugs for children and adolescents.

• Accurate and up-to-date
• Specific to children and adolescents
• Charts and tables help decision-making
• Icons and full color

Many psychotropic drugs are used to treat childhood and adolescent mental illness on the basis of efficacy in adults, despite not being currently approved for use in the young. The lack of approval does not necessarily reflect lack of safety or efficacy, but it does reflect a lack of controlled studies.

The Clinical Handbook of Psychotropic Drugs for Children and Adolescents is a unique resource to help you make the right choice for younger patients:

• Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions…) for a quick overview of treatment options
• Succinct, bulleted information on all classes of medication: on- and off-label indications, (US FDA, Health Canada), recommended dosages, US and Canadian trade names, side effects, interactions, pharmacodynamics, nursing implications, and much more – all you need to know for each class of drug
• Potential interactions and side effects summarized in comparison charts
• With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek
• Clearly written patient and caregiver information sheets for download as printable PDF files

This book is a must for all mental health professionals working with children and adolescents who need an up-to-date, easy-to use, comprehensive summary of all the most relevant information about psychotropic drugs.

Watch an interview with Dean Elbe about the new edition

New in this edition:

• Drugs for ADHD thoroughly revised and updated
• Antipsychotics with many changes and additions, including fully revised lab tests/monitoring
• Antidepressants fully revised, including new sections on irreversible MAO-B inhibitor and serotonin modulator and stimulator (SMS), revised frequency of adverse effects table and switching strategies recommendations
• Hypnotics completely revised
• Mood stabilizers fully revised and a new toxicity comparison table added
• Drugs of abuse and treatment of substance use disorders comprehensively revised
• New unapproved treatments with significant updates, including: anti-inflammatories and NMDA agents in anxiety/OCD, cannabis use disorder, and irritability of autism
• New agents include: Third generation antipsychotics brexpiprazole and cariprazine, orexin receptor antagonist suvorexant, selective melatonin agonist tasimelteon, serotonin modulator and stimulator vortioxetine
• New formulations and trade names include: Adasuve, Alprazolam Intensol, Aptensio XR, Aristada, Belbuca, Belsomra, Brintellix, Bunavail, Cotempla XR-ODT, Dyanavel XR, Eldepryl, EMSAM, Evekeo, Hemangeol, Hetlioz, Innopran XL, Invega Trinza, Khedezla, Metadol-D, Mydayis, NyQuil, Quillichew ER, Quillivant XR, Rexulti, Tegretol (liquid), Trintellix, Versacloz, Vraylar, Zelapar, Zenzedi

To the patient and caregiver information sheets

Do you want print and online? Deal with adults and children? Then combine CHPD publications and save. Click here for more information.